ASSESSMENT OF CIRCULATING CELL FREE DNA IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Deghady, Akram Abdel Moneim; Elsayed &lrm;, Amr Abdel Aziz; Abdelrahman, Ahmed Shehata; Eldabah, Nermeen Ahmed Mohamed; Mamdouh Elbordiny, Wessal Magdy

doi:10.21608/alexpo.2024.279291.1816

ASSESSMENT OF CIRCULATING CELL FREE DNA IN EGYPTIAN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

Document Type : Preliminary preprint short reports of original research

Authors

¹ Department of Clinical and Chemical Pathology, Faculty of Medicine, Alexandria University

² Department of Clinical Oncology and Nuclear Medicine*, Faculty of Medicine, Alexandria University

³ Departments of internal medicine, Hematology, Faculty of Medicine, University of Alexandria, Egypt

⁴ Department of Clinical and Chemical Pathology , Faculty of Medicine, Alexandria University

10.21608/alexpo.2024.279291.1816

Abstract

Introduction
Diffuse large B-cell lymphoma (DLBCL) is the single most common type of lymphoma worldwide. (1) It is a clinically aggressive cancer that rapidly grows and usually metastasizes throughout the body at early stages yet it’s potentially curable; therefore, it requires early diagnosis, urgent treatment and close monitoring. In DLBCL, the diagnosis, prognosis and monitoring of the disease are currently based on clinical assessment, invasive biopsies, CT scans and PET scans. Those methods are highly valuable; however, there’s an urgent need for a simpler tool to assess prognosis, closely monitor the patient’s response to treatment and allow earlier detection of relapse. Circulating cell free DNA (ccfDNA) is this promising biomarker; the liquid gold that must be further studied to obtain such a simple accessible biomarker that can reflect so much information about the underlying malignant clone. Circulating cfDNA is mainly composed of double stranded DNA fragments circulating in the bloodstream of both healthy and diseased individuals. Normally, ccfDNA is present in low concentrations; however, ccfDNA levels are increased in certain conditions like pregnancy, malignant diseases and non-malignant diseases such as inflammatory conditions, autoimmune diseases, trauma, myocardial infarction stroke, sepsis and allograft transplant rejection. It has been found that circulating cfDNA in cancer patients show a different fragmentation profile from cfDNA in healthy individuals; therefore, the integrity of cfDNA has been investigated as a potential diagnostic and prognostic marker in several cancers.

Keywords